Tradestie Institutional Equity Comparison Engine

CELU vs OVID โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

OVID Overall Edge

OVID Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ovid Therapeutics Inc. Common Stock (OVID) driven by superior Valuation, Momentum & Technical, Options & Structure while CELU counters with relative strength in Growth & Margin. Fundamentally, CELU trades at N/M Forward P/E with -254.0% operating margin (-5.3% YoY revenue) versus OVID at 1.8x Forward P/E and -4693.7% operating margin (-88.3% YoY). In options structure, CELU sits in BREAKDOWN (50th %ile IV; Dealer Gamma Walls on Pro) against OVID sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner OVID
CELU N/M vs OVID 1.8x Fwd P/E
Growth & Margin Winner CELU
Op Margin -254.0% vs -4693.7% ยท YoY -5.3% vs -88.3%
Momentum & Technical Winner OVID
1Y -72.6% vs +71.9% ยท 52W Pos 2% vs 52%
Options & Structure Winner OVID
BREAKDOWN (50th %ile IV) vs BREAKDOWN (<1st %ile IV)
CELU NASDAQ
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap $15.2M
1M Return -55.9%
1Y Return -72.6%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 67.0 Mom 55.0
OVID NASDAQ
Ovid Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.20
-5.98% 1D
Market Cap $424.6M
1M Return -7.17%
1Y Return +71.88%
Forward P/E 1.8x
Unified AI Score
52.3 / 100 HOLD
Tech 30.0 Fund 48.0 Flow 68.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CELU -72.6% OVID +71.88% Spread: +144.48 pp (OVID Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CELU Revenue OVID Revenue CELU Op. Margin OVID Op. Margin Margin Edge
FY2020 $10M $10M -1064.0% -645.4% OVID
FY2021 $20M $210M -511.2% 59.6% OVID
FY2022 $20M $0M -142.4% -3696.4% CELU
FY2023 $20M $0M -844.4% -15122.7% CELU
FY2024 $50M $0M -70.7% -10933.7% CELU
FY2025 $30M $10M -230.9% -585.2% CELU

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CELU (2) vs OVID (8)
Institutional Metric CELU OVID Criterion Row Winner
Market Capitalization Scale $15.2M $424.6M Larger Scale OVID
Trailing P/E Ratio Valuation N/M 1.8x Lower Multiple OVID
Forward P/E Ratio Valuation N/M 1.8x Lower Multiple OVID
Revenue Growth (YoY) Growth -5.3% -88.3% Higher Growth CELU
Operating Margin (TTM) Profitability -254.0% -4693.7% Higher Margin CELU
Net Profit Margin Profitability -245.7% 0.0% Higher Margin OVID
Return on Equity (ROE) Capital Efficiency -6367.2% -35.4% Higher ROE OVID
52-Week Range Position Momentum 2% ($0โ€“$3) 52% ($1โ€“$3) Stronger Trend OVID
Beta / 30D Volatility Risk Regime 2.01ฮฒ ยท 135% Vol 1.04ฮฒ ยท 97% Vol Lower Realized Risk OVID
Unified Institutional Score Composite Signal 42.9 / 100 (HOLD) 52.3 / 100 (HOLD) Higher Composite OVID

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CELU vs OVID Buy Guide
CELU BREAKDOWN
60d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CELU Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OVID BREAKDOWN
154d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live OVID Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CELU nor OVID registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.